- Previous Close
12.00 - Open
12.00 - Bid 7.97 x 38800
- Ask 9.03 x 45100
- Day's Range
12.00 - 12.00 - 52 Week Range
9.20 - 12.24 - Volume
100 - Avg. Volume
0 - Market Cap (intraday)
5.44B - Beta (5Y Monthly) 0.58
- PE Ratio (TTM)
20.07 - EPS (TTM)
0.61 - Earnings Date Mar 3, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date Sep 18, 2024
- 1y Target Est
--
Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and supplies specialty and branded pharmaceutical products worldwide. It operates in Commercial Pharmaceuticals and Manufacturing segments. The company provides general, local, and regional anesthetic; low molecular weight heparin; regional and spinal anesthetic; and opioid analegesic under the Diprivan, Emla, Fraxiparine, Marcaine, Ultiva, and Xylocaine brand names. It also offers such as sleeping aid, thyroid hormone, immunosuppressant, iron supplement, analgesic anti-inflammatory, and hormone replacement therapy under the Circadin, Eltroxin, Foxair, Imuran, Maltofer, Mybulen, and Ovestin brand names. In addition, the company manufactures and sells active pharmaceutical ingredients and finished dose form products. Aspen Pharmacare Holdings Limited was founded in 1850 and is headquartered in Durban, South Africa.
www.aspenpharma.com8,867
Full Time Employees
June 30
Fiscal Year Ends
Sector
Recent News: APNHF
View MorePerformance Overview: APNHF
Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is All Share Index (^J203.JO) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: APNHF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: APNHF
View MoreValuation Measures
Market Cap
3.98B
Enterprise Value
5.53B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
9.84%
Return on Assets (ttm)
4.21%
Return on Equity (ttm)
5.25%
Revenue (ttm)
45.53B
Net Income Avi to Common (ttm)
4.48B
Diluted EPS (ttm)
0.61
Balance Sheet and Cash Flow
Total Cash (mrq)
6.8B
Total Debt/Equity (mrq)
41.69%
Levered Free Cash Flow (ttm)
1.46B